+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Reduced use of third-generation cephalosporins decreases the acquisition of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae



Reduced use of third-generation cephalosporins decreases the acquisition of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae



Infection Control and Hospital Epidemiology 25(10): 832-837



To identify risk factors for the respiratory acquisition of extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae among patients admitted to a neurosurgical intensive care unit (NSICU) and to modify them without changing general infection control measures. Nested case-control and intervention study. A 1,200-bed, tertiary-care teaching hospital with a 17-bed NSICU. Sputa of all patients admitted to the NSICU were cultured weekly during the study. From October 2002 through February 2003, 29 case-patients from whose sputum ESBL-producing K. pneumoniae was isolated were detected and 59 controls-patients were randomly selected among patients without any positive isolate of ESBL-producing K. pneumoniae. After analyzing the risk factors, we intervened to modify them and compared the acquisition rate of ESBL-producing K. pneumoniae before (October 2002 to February 2003) and after (April to August 2003) the intervention. Multivariate analysis showed that prior exposure to third-generation cephalosporins (TGCs) (OR, 6.0; CI95, 1.9 to 18.6; P = .002) was an independent risk factor of ESBL-producing K. pneumoniae acquisition. The neurosurgical team was notified of the result, and the infectious diseases specialist visited the NSICU three times a week to regulate TGC use during the intervention period. Patients admitted before the intervention were older than patients admitted after. The respiratory acquisition of ESBL-producing K. pneumoniae per 1,000 patient-days (13.5 [CI95, 8.9 to 18.1] vs 2.7 [CI95, 0.9 to 4.6]) and the antimicrobial use density of TGCs (38.2 +/- 5.0 vs 17.3 +/- 2.6; P < .001) decreased significantly after the intervention. Prior exposure to TGCs was an independent risk factor for the respiratory acquisition of ESBL-producing K. pneumoniae, and less use of TGCs was associated with a decrease in acquisition.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 050140739

Download citation: RISBibTeXText

PMID: 15518024

DOI: 10.1086/502304


Related references

Infections by OXA-48-like-producing Klebsiella pneumoniae non-co-producing extended-spectrum beta-lactamase: Can they be successfully treated with cephalosporins?. Journal of Global Antimicrobial Resistance 19: 28-31, 2019

Clinical outcome of patients with extended-spectrum beta-lactamase -producing Klebsiella pneumoniae and Escherichia coli bacteremia after treatment with expanded-spectrum cephalosporins. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 166, 1999

Extended spectrum beta lactamase (ESBL) mediated resistance to third generation cephalosporins among Klebsiella pneumoniae in Chennai. Indian Journal of Medical Microbiology 20(2): 92-95, 2007

Extended spectrum beta-lactamase mediated resistance to third generation cephalosporins in Klebsiella pneumoniae in Nagpur, central India. Indian Journal of Medical Research 105: 158-161, 1997

Risk factors for neonatal acquisition of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 307, 2002

Recurrent Klebsiella pneumoniae mycotic aneurysm in a diabetic patient and emergence of an extended-spectrum beta-lactamase (CTX-M-24)-containing Klebsiella pneumoniae strain after prolonged treatment with first-generation cephalosporins for mycotic aneurysm. Microbial Drug Resistance 10(4): 359-363, 2004

Impact of third-generation cephalosporins restriction on the control of an extended-spectrum beta-lactamases producing Klebsiella pneumoniae outbreak in ICU. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 36: 222, 1996

Transfer of resistance to 3rd generation cephalosporins and aztreonam in strains of Klebsiella pneumoniae producing extended spectrum beta-lactamases. Epidemiologie Mikrobiologie Imunologie 48(1): 21-27, 1999

Transferable resistance to 3rd generation cephalosporins and aztreonam in strains of Klebsiella pneumoniae producing beta-lactamases with an extended spectrum (ESBL). Epidemiologie Mikrobiologie Imunologie 48(1): 21-27, 1999

Extended Spectrum Beta-Lactamase-producing Klebsiella pneumoniae outbreaks during a third generation cephalosporin restriction policy. Journal of ChemoTherapy 17(1): 66-73, 2005

Novel extended spectrum beta lactamase tem 22 in klebsiella pneumoniae conferring higher resistance to aztreonam than to extended spectrum cephalosporins. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 32: 322, 1992

Risk factors for acquisition of extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae in North-Indian hospitals. Saudi Journal of Biological Sciences 22(1): 37-41, 2015

Novel, plasmid-encoded, TEM-derived extended-spectrum beta-lactamase in Klebsiella pneumoniae conferring higher resistance to aztreonam than to extended-spectrum cephalosporins. Antimicrobial Agents and ChemoTherapy 37(9): 2020-2023, 1993

Risk factors for acquisition of CTX-M-15 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae during an outbreak in a neonatal intensive care unit in Norway. Scandinavian Journal of Infectious Diseases 45(1): 54-58, 2013

Risk factors for extended-spectrum beta-lactamase-producing Serratia marcescens and Klebsiella pneumoniae acquisition in a neonatal intensive care unit. Journal of Hospital Infection 67(2): 135-141, 2007